Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors

Abstract

Our previous study indicated that a chiral compound 071031B was a novel serotonin and noradrenaline reuptake inhibitor with superior antidepressant activity compared to duloxetine. The present study aimed to investigate chiral pharmacology differences of 071031B enantiomers, S-071031B and R-071031B, and disclose mechanisms underlying the behavioral differences based on target profiles and pharmacokinetic profiles. In vivo behavioral tests indicated that S-071031B was more potent than R-071031B in two depression models (the forced swimming test in mice and rats) and two pain models (the acetic acid-induced writhing and formalin tests in mice). In vitro assays revealed that both S-071031B and R-071031B showed high affinity for human serotonin transporters and norepinephrine transporters with equal potency, and showed consistently equipotent inhibitory effects on serotonin and norepinephrine uptake. Pharmacokinetic studies demonstrated that oral availability and hepatic metabolism, rather than pH stability, intestinal transport, and plasma binding, contributed to enantiomers’ behavioral differences. Based on these findings, it is suggested that S-071031B is a more active enantiomer, and the differential pharmacokinetic profiles, but not target affinity, contribute to differences of S-071031B and R-071031B in behavioral pharmacology. Moreover, current PK-PD study may provide positive exploration for chiral antidepressants development.

Keywords

Antidepressants serotonin and norepinephrine uptake inhibitors chiral pharmacology behavioral pharmacology pharmacokinetics

Get full access to this article

View all access options for this article.

References

Auclair

Martel

Assié

. (2013) Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety. Neuropharmacology 70: 338–347.

Bannister

Bee

Dickenson

(2009) Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 6: 703–712.

Blaschke

Kraft

Fickentshcer

. (1979) Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers. Arzneim Forsch 29: 1640–1642.

Bliss

(1967) Statistics in Biology. New York: McGraw-Hill Book Company.

Bymaster

Lee

Knadler

. (2005) The dual transporter inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 11: 1475–1493.

Cryan

Markou

Lucki

(2002) Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci 23: 238–245.

Davies

Morris

(1993) Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093–1095.

Fishbain

(2000) Evidence-based data on pain relief with antidepressants. Ann Med 32: 305–316.

Holliday

Benfield

(1995) Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49: 280–294.

10.

Howell

Hicks

Scatina

. (1994) Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24: 315–327.

11.

Hutt

Vanetova

(2003) The chiral switch: The development of single enantiomer drugs from racemates. Acta Facult Pharm Univ Comenianae 50: 7–23.

12.

Jones

Peters

Shannon

(2005) Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 312: 726–732.

13.

Judd

Akiskal

Maser

. (1998) Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50: 97–108.

14.

Kimoto

Takanashi

Mukai

. (2009) Effect of adrenergic stimulation on drug absorption via passive diffusion in Caco-2 cells. Int J Pharm 368: 31–36.

15.

LaCroix-Fralish

Smith

. (2009) The β3 subunit of the Na⁺, K⁺-ATPase mediates variable nociceptive sensitivity in the formalin test. Pain 144: 294–302.

16.

Lee

Chen

(2010) A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 11: 2813–2825.

17.

Feng

Gong

. (2014) Determination of pharmacokinetics differences of ammuxetine isomers in rat plasma using on-line solid phase extraction with liquid chromatography-tandem mass spectrometry. Chin J Anal Chem 42: 1717–1722.

18.

Millan

(2009) Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs. Neurotherapeutics 6: 53–77.

19.

Nagilla

Frank

Jolivette

. (2006) Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol Methods 53: 106–116.

20.

National Institutes of Health (1978) Guide for the Care and Use of Laboratory Animals. NIH Publications No. 8023, Report no. DHEW-5I/1-78-23. Bethesda: NIH.

21.

Pae

(2011) Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 12: 2923–2928.

22.

Pergolizzi

Jr Raffa

Taylor

Jr . (2013) A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract 13: 239–252.

23.

Porsolt

Anton

Blavet

. (1978) Behavioural despair in rats: A new model sensitive to antidepressive treatments. Eur J Pharmacol 47: 379–391.

24.

Srinivas

Barbhaiya

Midha

(2001) Enantiomeric drug development: Issues, considerations, and regulatory requirements. J Pharm Sci 90: 1205–1215.

25.

Stahl

Grady

Moret

. (2005) SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10: 732–747.

26.

Staiger

Gaster

Sullivan

. (2003) Systematic review of antidepressants in the treatment of chronic low back pain. Spine (Phila Pa 1976) 28: 2540–2545.

27.

Tang

. (2015) Study on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique. Biomed Chromatogr 29: 1137–1145.

28.

Thase

Entsuah

Rudolph

(2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178: 234–241.

29.

Thase

Pritchett

Ossanna

. (2007) Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharm 27: 672–676.

30.

US Food and Drug Administration (1992) Development of new stereoisomeric drugs. Available at: www.fda.gov/drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122883.htm# (accessed 7 December 2016).

31.

Wong

Bymaster

Mayle

. (1993) LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8: 23–33.

32.

Xue

Jin

Chen

. (2013a) Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor. Eur Neuropsychopharmacol 23: 728–741.

33.

Xue

Zhang

Jin

. (2013b) The discovery of 071031B, a novel serotonin and noradrenaline reuptake inhibitor. Neurosci Lett 544: 68–73.

34.

Yamashita

Furubayashi

Kataoka

. (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10: 195–204.

35.

Zhuang

Deng

. (2011) Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes. Acta Pharmacol Sin 32: 1276–1284.